Improved Low Contrast Visual Acuity, Reduction in Retinal Ganglion Cell Loss, and Neurofilaments-light with Privosegtor in Acute Optic Neuritis: Results from a Multicenter, Randomized, Placebo-controlled, Double-masked Trial (AAN 2026) - Feb 1, 2026 - Pres time: Apr 21, 2026; 10:15 AM - 10:30 AM; Location: McCormick Place West | W375de; In-Person; Virtual; "Objective:To evaluate the efficacy, safety, and tolerability of privosegtor in acute optic neuritis (AON).Background:Privosegtor (OCS-05), a peptoid small molecule with neuroprotective activity, is being studied as a treatment for AON.Design/The ACUITY phase 2 multi-center, randomized, double-masked, placebo-controlled study evaluated privosegtor (2 or 3 mg/kg IV daily for 5 days) as an addition to methylprednisolone IV in patients with AON of less than 12 days duration, excluding AQP4+ patients. Privosegtor demonstrated significant improvement in visual function, reduced retinal ganglion cell damage, and lowered NfL changes, suggesting neuroaxonal preservation. The drug was well-tolerated by participants."
Clinical • Ocular Inflammation • Ophthalmology • Optic Neuritis • Plasma NfL
|
|
Pablo Villoslada1; Celine Louapre2; Sophie Bonnin3; Louise-Laure Mariani2; Mikael Cohen4; Caroline Froment5; Mark Kupersmith6; Leonard A Levin7; Sabri Markabi8; Caroline Papeix2; Valérie Touitou2; Rossella Medori9; Marion R. Munk10; Martin S. Zinkernagel10; Sebastian Wolf10
|